The potential for therapy of immune disorders with gene therapy

Pediatric Clinics of North America

Volumn 47, Issue 6, 2000, Pages 1389-1407

  Candotti, Fabio ^b  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE;

ADENO ASSOCIATED VIRUS; CHRONIC GRANULOMATOUS DISEASE; COMBINED IMMUNODEFICIENCY; ENZYME DEFICIENCY; GENE CONTROL; GENE THERAPY; GENE TRANSFER; HUMAN; HYPERIMMUNOGLOBULINEMIA; IMMUNE DEFICIENCY; LENTIVIRINAE; LEUKOCYTE ADHESION DEFICIENCY; RETROVIRUS; REVIEW; X CHROMOSOME LINKED DISORDER;

EID: 0034535687     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-3955(05)70277-7     Document Type: Article

References (86)

1. Human gene marker/therapy clinical protocols
2. Human gene therapy
3. Human immunodeficiency virus type 2 lentivirus vectors for gene transfer: Expression and potential for helper virus-free packaging
4. Identification of the homologous beige and Chediak-Higashi syndrome genes
5. + cells derived from a patient with leukocyte adhesion deficiency type 1
6. + cells
7. A newly discovered class of human hematopoietic cells with SCID-repopulating activity
8. The ADA human gene therapy clinical protocol
9. T lymphocyte-directed gene therapy for ADA-SCID: Initial trial results after 4 years
10. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients
11. Correction of defective expression in MHC class II deficiency (bare lymphocyte syndrome) cells by retroviral transduction of CIITA
12. Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice
13. Human severe combined immunodeficiency: Genetic, phenotypic, and functional diversity in one hundred eight infants
14. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency
15. Virus-specific immunity after gene therapy in a murine model of severe combined immunodeficiency
16. Restoration of lymphocyte function in Janus kinase 3-deficient mice by retroviral-mediated gene transfer
17. Retroviral-mediated WASP gene transfer corrects defective actin polymerization in B-cell lines from Wiskott-Aldrich syndrome patients carrying 'null' mutations
18. Retroviral-mediated gene correction for X-linked severe combined immunodeficiency
19. In vitro correction of JAK3-deficient severe combined immunodeficiency by retroviral-mediated gene transduction
20. Structural and functional basis for JAK3-deficient severe combined immunodeficiency
21. Late diagnosis and correction of purine nucleoside phosphorylase deficiency with allogeneic bone marrow transplantation
22. -) human hematopoietic cells by HIV-1-based lentiviral vectors
23. Role of interleukin-2 (IL-2), IL-7, and IL-15 in natural killer cell differentiation from cord blood hematopoietic progenitor cells and from γc transduced severe combined immunodeficiency X1 bone marrow cells
24. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
25. High-titer packaging cells producing recombinant retroviruses resistant to human serum
26. Lymphocytes as cellular vehicles for gene therapy in mouse and man
27. The CD34 molecule and hematopoietic progenitor cell studies: A challenge in clinical medicine
28. European experience of bone-marrow transplantation for severe combined immunodeficiency
29. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species
30. Gene therapy using retroviral vectors
31. -) X-linked severe combined immunodeficiency hematopoietic progenitor cells in murine fetal thymic organ cultures
32. Gamma-c gene transfer into SCID X1 patients' B-cell lines restores normal high-affinity interleukin-2 receptor expression and function
33. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: A European retrospective study of 116 patients
34. Immunodeficiency caused by adenosine deaminase deficiency
35. Expression of human adenosine deaminase from various strong promoters after gene transfer into human hematopoietic cell lines
36. Bone marrow gene transfer in three patients with adenosine deaminase deficiency
37. Expression of human Wiskott-Aldrich syndrome protein in patients' cells leads to partial correction of a phenotypic abnormality of cell surface glycoproteins
38. The use of gene-modified tumor-infiltrating lymphocytes for cancer therapy
39. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors
40. Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combination with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor
41. The current status of gene therapy using hematopoietic stem cells
42. + cells in ADA-deficient SCID neonates
43. An in vivo animal model of gene therapy for leukocyte adhesion deficiency
44. The molecular basis of X-linked severe combined immunodeficiency: The role of the interleukin-2 receptor γ chain as a common γ chain, γc
45. The clinical spectrum of X-linked hyper IgM syndrome
46. + peripheral blood progenitors as a target for genetic correction of the two flavocytochrome b558 defective forms of chronic granulomatous disease
47. Restoration of lymphoid populations in a murine model of X-linked severe combined immunodeficiency by a gene-therapy approach
48. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)
49. + cells
50. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease
51. Purine nucleoside phosphorylase deficiency
52. Retrovirus packaging cells
53. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus
54. + cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors
55. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector
56. Gene therapy for AIDS using retroviral mediated gene transfer to deliver HIV-1 antisense TAR and transdominant Rev protein genes to syngeneic lymphocytes in HIV-1 infected identical twins
57. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
58. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector
59. - subset using highly purified recombinant adeno-associated viral vector preparations that are free of helper virus and wild-type AAV
60. Correction of proliferative responses in purine nucleoside phosphorylase (PNP)-deficient T lymphocytes by retroviral-mediated PNP gene transfer and expression
61. - cells in lymphohematopoiesis
62. Signaling via IL-2 and IL-4 in JAK3-deficient severe combined immunodeficiency lymphocytes: JAK3-dependent and -independent pathways
63. Gene transfer vectors derived from equine infectious anemia virus
64. Successful peripheral T lymphocyte-directed gene transfer for a patient with severe combined immune deficiency due to adenosine deaminase deficiency
65. Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell
66. Lymphoid development and function in X-linked severe combined immunodeficiency mice after stem cell gene therapy
67. Novel human immunodeficiencies reveal the essential role of type-I cytokines in immunity to intracellular bacteria
68. Identification of a human immunodeficiency virus type 2 (HIV-2) encapsidation determinant and transduction of nondividing human cells by HIV-2 based lentivirus vectors
69. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors
70. Efficient retroviral transduction of human bone marrow progenitor and long-term culture-initiating cells: Partial reconstitution of cells from patients with X-linked chronic granulomatous disease by gp91-phox expression
71. Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles
72. Mutation of Jak3 in a patient with SCID: Essential role of Jak3 in lymphoid development
73. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM
74. RAG mutations in human B cell-negative SCID
75. Peripheral blood progenitors as a target for genetic correction of p47(phox)-deficient chronic granulomatous disease
76. Stable and functional lymphoid reconstitution of common cytokine receptor gamma chain deficient mice by retroviral-mediated gene transfer
77. Severe combined immunodeficiency: A retrospective single-center study of clinical presentation and outcome in 117 patients
78. Reconstitution of T cell receptor signaling in ZAP-70-deficient cells by retroviral transduction of the ZAP-70 gene
79. Correction of interleukin-2 receptor function in X-SCID lymphoblastoid cells by retrovirally mediated transfer of the gamma-c gene
80. HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated G0/G1 human hematopoietic stem cells
81. Partial V(D)J recombination activity leads to Omenn syndrome
82. Genetic correction of p67phox deficient chronic granulomatous disease using peripheral blood progenitor cells as a target for retrovirus mediated gene transfer
83. Expression of human CD18 in murine granulocytes and improved efficiency for infection of deficient human lymphoblasts
84. Generation of high-titer pseudotyped retroviral vectors with very broad host range
85. KDR receptor: A key marker defining hematopoietic stem cells
86. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo